<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37321640</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0315-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>1302</StartPage><EndPage>1309</EndPage><MedlinePgn>1302-1309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.2023-0060</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Concerns about the affordability of medications are common in systemic lupus erythematosus (SLE), but the relationship between medication cost concerns and health outcomes is poorly understood. We assessed the association of self-reported medication cost concerns and patient-reported outcomes (PROs) in a multiethnic SLE cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The California Lupus Epidemiology Study is a cohort of individuals with physician-confirmed SLE. Medication cost concerns were defined as having difficulties affording SLE medications, skipping doses, delaying refills, requesting lower-cost alternatives, purchasing medications outside the United States, or applying for patient assistance programs. Linear regression and mixed effects models assessed the cross-sectional and longitudinal association of medication cost concerns and PROs, respectively, adjusting for age, sex, race and ethnicity, income, principal insurance, immunomodulatory medications, and organ damage.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 334 participants, medication cost concerns were reported by 91 (27%). Medication cost concerns were associated with worse Systemic Lupus Activity Questionnaire (SLAQ; beta coefficient [&#x3b2;] 5.9, 95% CI 4.3-7.6; <i>P</i> &lt; 0.001), 8-item Patient Health Questionnaire depression scale (PHQ-8; &#x3b2; 2.7, 95% CI 1.4-4.0; <i>P</i> &lt; 0.001), and Patient-Reported Outcomes Measurement Information System (PROMIS; &#x3b2; for physical function -4.6, 95% CI -6.7 to -2.4; <i>P</i> &lt; 0.001) scores after adjusting for covariates. Medication cost concerns were not associated with significant changes in PROs over 2-year follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">More than a quarter of participants reported at least 1 medication cost concern, which was associated with worse PROs. Our results reveal a potentially modifiable risk factor for poor outcomes rooted in the unaffordability of SLE care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the Journal of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6999-6297</Identifier><AffiliationInfo><Affiliation>A. Aguirre, MD, M. Dall'Era, MD, J. Yazdany, MD, MPH, Division of Rheumatology, University of California, San Francisco, California; alfredo.aguirre@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeQuattro</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8339-5666</Identifier><AffiliationInfo><Affiliation>K. DeQuattro, MD, Division of Rheumatology, University of Pennsylvania, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiboski</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9257-2609</Identifier><AffiliationInfo><Affiliation>S. Shiboski, PhD, Department of Epidemiology &amp; Biostatistics, University of California, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8146-2519</Identifier><AffiliationInfo><Affiliation>P. Katz, PhD, Department of Medicine, University of California, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenlund</LastName><ForeName>Kurt J</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-9185-2107</Identifier><AffiliationInfo><Affiliation>K.J. Greenlund, PhD, Epidemiology and Surveillance Branch, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbour</LastName><ForeName>Kamil E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0003-0546-6742</Identifier><AffiliationInfo><Affiliation>K.E. Barbour, PhD, MPH, Lupus and Interstitial Cystitis Programs, Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1244-6443</Identifier><AffiliationInfo><Affiliation>C. Gordon, MD, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanata</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6017-4921</Identifier><AffiliationInfo><Affiliation>C. Lanata, MD, Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Section, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Criswell</LastName><ForeName>Lindsey A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-0761-7543</Identifier><AffiliationInfo><Affiliation>L.A. Criswell, MD, MPH, DSc, Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Section, National Institutes of Health, Bethesda, Maryland USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'Era</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7439-2316</Identifier><AffiliationInfo><Affiliation>A. Aguirre, MD, M. Dall'Era, MD, J. Yazdany, MD, MPH, Division of Rheumatology, University of California, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdany</LastName><ForeName>Jinoos</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3508-4094</Identifier><AffiliationInfo><Affiliation>A. Aguirre, MD, M. Dall'Era, MD, J. Yazdany, MD, MPH, Division of Rheumatology, University of California, San Francisco, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AR074534</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070155</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP006486</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Rheumatol. 2023 Oct;50(10):1205-1207</RefSource><PMID Version="1">37657797</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug costs</Keyword><Keyword MajorTopicYN="N">healthcare disparities</Keyword><Keyword MajorTopicYN="N">patient-reported outcome measures</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement><b>Conflicts of interest</b>: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>20</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37321640</ArticleId><ArticleId IdType="mid">NIHMS1906419</ArticleId><ArticleId IdType="pmc">PMC10543599</ArticleId><ArticleId IdType="doi">10.3899/jrheum.2023-0060</ArticleId><ArticleId IdType="pii">jrheum.2023-0060</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015;74:1706&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M, Fuzzi E, Loredo Martinez M, Depascale R, Fredi M, Gatto M, et al. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford) 2022;61:688&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">33909900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K, Loundou A, Bouillet L, Burtey S, et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann Rheum Dis 2022;81:1420&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484365</ArticleId><ArticleId IdType="pubmed">35725295</ArticleId></ArticleIdList></Reference><Reference><Citation>Minhas D, Marder W, Harlow S, Hassett AL, Zick SM, Gordon C, et al. Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. Arthritis Care Res (Hoboken) 2021;73:1561&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9219566</ArticleId><ArticleId IdType="pubmed">32741110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis &amp; Rheumatology 2017;69:1996&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891237</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: Estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol 2021;art.41632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8169527</ArticleId><ArticleId IdType="pubmed">33474834</ArticleId></ArticleIdList></Reference><Reference><Citation>Heisler M, Choi H, Rosen AB, Vijan S, Kabeto M, Langa KM, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care 2010;48:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034735</ArticleId><ArticleId IdType="pubmed">20068489</ArticleId></ArticleIdList></Reference><Reference><Citation>Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, et al. Persistent medication affordability problems among disabled Medicare beneficiaries after Part D, 2006&#x2013;2011. Med Care 2014;52:951&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539257</ArticleId><ArticleId IdType="pubmed">25122530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Lobo JM, Kim S, Sohn M-W. Cost-related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract 2018;143:24&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204232</ArticleId><ArticleId IdType="pubmed">29944967</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Alsten SC, Harris JK. Cost-Related Nonadherence and Mortality in Patients With Chronic Disease: A Multiyear Investigation, National Health Interview Survey, 2000&#x2013;2014. Prev Chronic Dis 2020;17:E151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7735485</ArticleId><ArticleId IdType="pubmed">33274701</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha MB, Valero-Elizondo J, Yahya T, Caraballo C, Khera R, Patel KV, et al. Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013&#x2013;2018. Diabetes Care 2022;45:594&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">35015860</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre A, Izadi Z, Trupin L, Barbour KE, Greenlund KJ, Katz P, et al. Race, Ethnicity, and Disparities in the Risk of End-Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care &amp; Research 2023;75:34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587136</ArticleId><ArticleId IdType="pubmed">35452566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MR, Piette JD, Resnicow K, Kowalski-Dobson T, Heisler M. Social Determinants of Health, Cost-related Nonadherence, and Cost-reducing Behaviors Among Adults With Diabetes: Findings From the National Health Interview Survey. Med Care 2016;54:796&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945373</ArticleId><ArticleId IdType="pubmed">27219636</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009;114:163&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18752852</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter JP. The Promise of Patient-Reported Outcomes Measurement Information System-Turning Theory into Reality: A Uniform Approach to Patient-Reported Outcomes Across Rheumatic Diseases. Rheum Dis Clin North Am 2016;42:377&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133496</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz P, Yazdany J, Trupin L, Rush S, Helmick CG, Murphy LB, et al. Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care Res (Hoboken) 2019;71:1630&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482092</ArticleId><ArticleId IdType="pubmed">30354017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdany J, Trupin L, Gansky SA, Dall&#x2019;era M, Yelin EH, Criswell LA, et al. The Brief Index of Lupus Damage (BILD): A patient-reported measure of damage in SLE. Arthritis Care Res (Hoboken) 2011;63:1170&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149719</ArticleId><ArticleId IdType="pubmed">21584946</ArticleId></ArticleIdList></Reference><Reference><Citation>Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007;22:864&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2219866</ArticleId><ArticleId IdType="pubmed">17410403</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Valero-Elizondo J, Das SR, Virani SS, Kash BA, de Lemos JA, et al. Cost-Related Medication Nonadherence in Adults With Atherosclerotic Cardiovascular Disease in the United States, 2013 to 2017. Circulation 2019;140:2067&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31760784</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol 2013;40:137&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3815617</ArticleId><ArticleId IdType="pubmed">23322458</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, O&#x2019;Malley KJ, Janssen NM, Marcus DM, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 2005;32:913&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15868630</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Corneli AL, Dombeck C, Swezey T, Rogers JL, Criscione-Schreiber LG, et al. Barriers to Taking Medications for Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers, and Clinic Staff. Arthritis Care Res (Hoboken) 2022;74:1459&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8417148</ArticleId><ArticleId IdType="pubmed">33662174</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Qu H, Yazdany J, Chatham W, Dall&#x2019;era M, Shewchuk RM. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. J Rheumatol 2015;42:1616&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26178276</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz P, Pedro S, Alemao E, Yazdany J, Dall&#x2019;Era M, Trupin L, et al. Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatol 2020;2:53&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957915</ArticleId><ArticleId IdType="pubmed">31943975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin E, Trupin L, Yazdany J. A prospective study of the impact of current poverty, history of poverty, and exiting poverty on accumulation of disease damage in systemic lupus erythematosus. Arthritis Rheumatol 2017;69:1612&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529220</ArticleId><ArticleId IdType="pubmed">28480630</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000;9:601&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035435</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009;61:240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875189</ArticleId><ArticleId IdType="pubmed">19177526</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaddy MT, Cook CL, O&#x2019;Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T 2012;37:45&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278192</ArticleId><ArticleId IdType="pubmed">22346336</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari P, Cross W, Crawford K. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review. Semin Arthritis Rheum 2018;48:12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496225</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:953&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928475</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard AJ, Sleath B, Blalock SJ, Roth M, Weinberger M, Tudor G, et al. Predictors of rheumatoid arthritis patient-physician communication about medication costs during visits to rheumatologists. Arthritis Care Res (Hoboken) 2010;62:632&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20191466</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden JM, Graves AJ, Zhang F, Adams AS, Briesacher BA, Ross-Degnan D, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008;299:1922&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781951</ArticleId><ArticleId IdType="pubmed">18430911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009;48:266&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomanto Silva R, Swabe GM, Magnani JM. Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus. [abstract] Arthritis Rheumatol 2022; 74 (suppl 9):2215&#x2013;6.</Citation></Reference><Reference><Citation>Askanase AD, Castrej&#xf3;n I, Pincus T. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient Multidimensional Health Assessment Questionnaire and physician estimate of noninflammatory symptoms. J Rheumatol 2011;38:1309&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">21459938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Kesselheim AS, Rome BN. New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges. JAMA 2022;328:1041&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">35984652</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>